Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanamide SCHEMBL23319969 | 0.87 | — | — | |
| SCHEMBL899641 | 0.86 | HPGD (0.33) | — | |
| SCHEMBL98197 | 0.86 | — | — | |
| SCHEMBL23081736 | 0.86 | HPGD (0.33) | — | |
| SCHEMBL5355629 | 0.85 | — | — | |
| SCHEMBL10709604 | 0.83 | — | — | |
| SCHEMBL27867937 | 0.83 | — | — | |
| SCHEMBL135661 | 0.79 | CYP19A1 (0.30) | — | |
| SCHEMBL23407909 | 0.79 | CYP19A1 (0.30) | — | |
| SCHEMBL29211858 | 0.79 | CYP19A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016184543-A1 | REACTIVE MESOGENS | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | WO | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6369091-B1 | ANTIALLERGENS | AVANIR PHARMACEUTICALS | 2002-04-09 | — | — | US | disclosed |
| EP-1193558-A2 | Radiation-sensitive resin composition | JSR Corporation (JP) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | EPHX2 1249/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | EPHX2 1256/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | EPHX2 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.